Ocular Therapeutix announces first patient dosed in phase 1 clinical trial of OTX-CSI to treat dry eye disease

This article was originally published here

“We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease,” said Michael Goldstein, MD, MBA, Chief Medical Officer. “We believe that the intracanalicular

The post Ocular Therapeutix announces first patient dosed in phase 1 clinical trial of OTX-CSI to treat dry eye disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply